基于新兴技术的单克隆抗体药物的研究进展  

Research progress of emerging monoclonal antibody drugs based on new technologies

作　　者：王志明[1] 杨立霞[1] 贾寅星 贺丞 

机构地区：[1]华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室,石家庄050015

出　　处：《中国新药杂志》2012年第18期2149-2155,共7页Chinese Journal of New Drugs

基　　金：国家"973"科技重大专项(2010CB735605)

摘　　要：经过多年的发展,单克隆抗体已经成为一类重要的临床药物。随着抗体技术不断发展,新型抗体不断出现,推动了单克隆抗体药物的进一步发展。从临床前及临床各阶段在研的单克隆抗体药物数量可以看出,基于新兴技术的五类抗体药物:域抗体、抗体-药物共轭体、双特异性抗体、三功能抗体和Fc片段工程抗体呈现出旺盛的发展势头,有望在未来的单克隆抗体药物市场中发挥重要的作用。本文就这五类单克隆抗体药物的发展状况与在研药物作一简要综述。After years of development,monoclonal antibodies have become an important class of clinical drugs.With the continuous development of new antibody-based technologies,the monoclonal antibody drug is fast-growing.From preclinical to clinical phase of the study,antibody drugs are based on five types of emerging technologies： domain antibodies（DAbs）,antibody-drug conjugates（ADCs）,bispecific antibodies（BsAb）,trifunctional antibodies（TriomAb）,and Fc fragment engineered antibodies.These drugs are showing a strong momentum of development and expected to be more important in the monoclonal antibody drug market in the future.In this paper,we reviewed these five types of emerging technologies that sit within the fast-growing therapeutic monoclonal antibody sector.

关 键 词：单克隆抗体 新兴技术 域抗体 

分 类 号：R97[医药卫生—药品]